翰宇药业：HY3003减重创新药项目原料药已完成工艺开发，并开展月制剂、周制剂、口服三种剂型研究

Core Viewpoint - The company is actively advancing its innovative drug development, particularly in the area of weight loss medications and strategic partnerships for peptide drug commercialization [2] Group 1: Innovative Drug Development - The company has made significant breakthroughs in innovative drug research and development [2] - The innovative drug project HY3003 for weight loss has completed the process development of the active pharmaceutical ingredient and is exploring three dosage forms: monthly, weekly, and oral [2] - The nasal spray drug HY3000 has entered the Phase III clinical trial stage [2] Group 2: Strategic Partnerships - On July 31, the company established a strategic cooperation with Borui Pharmaceutical to leverage each other's strengths in peptide drug development and commercialization [2] - The partnership aims to achieve resource sharing and collaborative development to promote the commercialization of peptide raw materials and related overseas applications [2] - The company is also collaborating with Sinopharm Group on the research and development of Cannabidiol (CBD) in the CNS field [2]